Selective NR2B Antagonists for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NR2B NMDA receptor antagonists have limited therapeutic value due to poor pharmacokinetics, low bioavailability, and unfavorable CNS side effects, hindering their development as effective treatments for major depressive disorder and other neurological disorders.
Innovation Solution
Development of novel compounds of Formula I, including their pharmaceutically acceptable salts, which act as selective NR2B receptor ligands, offering improved binding affinity, inhibition efficacy, target selectivity, solubility, safety profiles, and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NMDA antagonists such as Ketamine are used, then rapid and enduring antidepressant properties are achieved, but CNS side effects including dissociative effects occur
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target the NR2B subunit of NMDA receptors rather than acting on all NMDA receptor subtypes. This subunit-specific selectivity localizes the therapeutic effect to NR2B-containing receptors in the brain, achieving antidepressant efficacy while minimizing off-target CNS side effects associated with non-selective antagonism
Solution Approach 2:
The invention segments the NMDA receptor system by focusing specifically on the NR2B subunit. By developing antagonists that selectively bind to NR2B rather than acting on the entire NMDA receptor complex, the patent divides the therapeutic action into a more precise subunit-specific mechanism, thereby improving the therapeutic index
2Object-affected harmful factors
If selective NR2B antagonists such as Traxoprodil are used, then improved side effect profile and sustained antidepressant response are achieved, but low bioavailability and poor pharmacokinetics hinder development
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of NR2B-selective antagonist compounds to optimize their pharmacokinetic properties. By varying structural parameters such as substituent groups, molecular weight, and lipophilicity, the invention aims to improve oral bioavailability and pharmacokinetic profile while maintaining NR2B selectivity and antidepressant efficacy
3Object-affected harmful factors
If NR2B-selective antagonists are developed, then favorable tolerability profile is achieved, but limited therapeutic value exists due to poor pharmacokinetics
Solution Approach 1:
The patent employs parameter changes by optimizing multiple molecular and pharmacokinetic parameters simultaneously. The invention modifies chemical structure parameters to enhance oral bioavailability, absorption, and metabolic stability, thereby converting NR2B-selective compounds with poor therapeutic value into viable therapeutic agents with both favorable tolerability and clinical utility
Data Source
AI summary
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.